A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".

Ogale, S.; Zerbini, CEH; Antoniou, M.; Freund, R.

doi:10.18553/jmcp.2020.26.12.1616

A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".

Details

Request a copy

Serval ID

serval:BIB_D4A7BE0C1D9D

Type

Article: article from journal or magazin.

Collection

Publications

Institution

Production externe

Title

A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".

Journal

Journal of managed care & specialty pharmacy

Author(s)

Ogale S., Zerbini CEH, Antoniou M., Freund R.

ISSN

2376-1032 (Electronic)

ISSN-L

2376-0540

Publication state

Published

Issued date

12/2020

Peer-reviewed

Oui

Volume

Number

Pages

1616-1617

Language

english

Notes

Publication types: Letter ; Comment
Publication Status: ppublish

Abstract

DISCLOSURES: The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc.

Keywords

Benzamides, Humans, Indazoles, Lung Neoplasms, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines

DOI

10.18553/jmcp.2020.26.12.1616

Pubmed

33251994

Web of science

000609241600015

Open Access

Yes

Create date

03/07/2023 16:12